Valuation: Soligenix, Inc.

Market Cap 7.92M 7.03M 6.58M 5.99M 11.28M 762M 11.44M 79.57M 30.8M 388M 29.73M 29.08M 1.25B P/E 2026 *
-0.66x
P/E 2027 * -0.91x
Enterprise Value 7.92M 7.03M 6.58M 5.99M 11.28M 762M 11.44M 79.57M 30.8M 388M 29.73M 29.08M 1.25B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.41%
Yield 2026 *
-
Yield 2027 * -
1 day+0.50%
1 week-5.80%
Current month+0.50%
1 month-3.24%
3 months-8.36%
6 months-68.37%
Current year-72.85%
1 week 0.36
Extreme 0.357
0.38
1 month 0.36
Extreme 0.355
0.4
Current year 0.28
Extreme 0.28
1.49
1 year 0.28
Extreme 0.28
1.97
3 years 0.28
Extreme 0.28
32
5 years 0.28
Extreme 0.28
268.8
10 years 0.28
Extreme 0.28
1,955.76
Manager TitleAgeSince
Chief Executive Officer 59 01/08/2006
Director of Finance/CFO 53 11/09/2019
Chief Tech/Sci/R&D Officer - 11/06/2026
Director TitleAgeSince
Chairman 59 08/10/2009
Director/Board Member 67 01/03/2009
Director/Board Member 80 01/10/2009
Date Insider Type Main position Quantity % Market Cap. Importance
9/17/26 A Free

Director

78,947 0.3627%
9/17/26 A Free

Director

78,947 0.3627%
9/17/26 A Free

Director

78,947 0.3627%
Change 5-day change 1-year change 3-year change Capi.($)
+0.50%-5.80%-70.66%-95.92% 7.92M
+4.16%+3.04%+49.37%+94.17% 74.41B
-0.61%+0.81%+27.25%+82.72% 59.26B
-2.54%-1.65%+4.86%+31.72% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-3.30%+2.26%+28.80%+21.93% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average -0.80%-1.05%+40.74%+129.17% 39.25B
Weighted average by Cap. -0.39%-0.32%+58.44%+146.04%

Financials

2026 *2027 *
Net sales - -
Net income -9.3M -8.26M -7.72M -7.04M -13.25M -895M -13.43M -93.45M -36.18M -456M -34.92M -34.16M -1.46B -10.1M -8.97M -8.39M -7.64M -14.39M -972M -14.59M -101M -39.29M -495M -37.92M -37.1M -1.59B
Net Debt - -
Logo Soligenix, Inc.
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
Employees
14
Date Price Change Volume
01/10/26 $0.3638 +0.50% 52,000
30/09/26 $0.3620 -0.82% 90,295
29/09/26 $0.3650 -3.29% 406,754
28/09/26 $0.3774 -1.80% 134,983
25/09/26 $0.3843 -0.49% 74,081
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3638USD
Average target price
1.375USD
Spread / Average Target
+277.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SNGX Stock